Literature DB >> 15797513

Cellular ligands of activating NK receptors.

Cristina Bottino1, Roberta Castriconi, Lorenzo Moretta, Alessandro Moretta.   

Abstract

Human natural killer (NK) cells are equipped with a series of surface receptors that recognise different cellular ligands on potential target cells. Some of these ligands [e.g. human leukocyte antigen (HLA) class I] prevent an NK-mediated attack by interacting with inhibitory NK receptors (e.g. killer Ig-like receptors). Other ligands interact with activating NK receptors that, once engaged, induce both cytotoxicity and lymphokine release. Tumour transformation (or viral infection) frequently results in downregulation of surface HLA class I molecules together with upregulation or de novo expression of ligands of triggering NK receptors. Thus, transformed cells can become highly susceptible to NK-mediated lysis. However, although NK cells use different means to identify and fight target cells, target cells have various strategies to hide themselves, and disarm or even confuse the immune system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15797513     DOI: 10.1016/j.it.2005.02.007

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  69 in total

1.  The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes.

Authors:  Francesca Bellora; Roberta Castriconi; Alessandra Dondero; Giorgio Reggiardo; Lorenzo Moretta; Alberto Mantovani; Alessandro Moretta; Cristina Bottino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-30       Impact factor: 11.205

2.  Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation.

Authors:  Andrea De Maria; Federica Bozzano; Claudia Cantoni; Lorenzo Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 3.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  Comparative study of immune regulatory properties of stem cells derived from different tissues.

Authors:  Mariano Di Trapani; Giulio Bassi; Mario Ricciardi; Emanuela Fontana; Francesco Bifari; Luciano Pacelli; Luca Giacomello; Michela Pozzobon; Francois Féron; Paolo De Coppi; Piero Anversa; Guido Fumagalli; Ilaria Decimo; Cedric Menard; Karin Tarte; Mauro Krampera
Journal:  Stem Cells Dev       Date:  2013-08-09       Impact factor: 3.272

Review 5.  A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions.

Authors:  Zhuwei Xu; Boquan Jin
Journal:  Cell Mol Immunol       Date:  2010-01       Impact factor: 11.530

6.  Regulation of human NK-cell cytokine and chemokine production by target cell recognition.

Authors:  Cyril Fauriat; Eric O Long; Hans-Gustaf Ljunggren; Yenan T Bryceson
Journal:  Blood       Date:  2009-12-01       Impact factor: 22.113

7.  The expanding genetic overlap between multiple sclerosis and type I diabetes.

Authors: 
Journal:  Genes Immun       Date:  2008-11-06       Impact factor: 2.676

8.  Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44.

Authors:  Nathan C Horton; Stephen O Mathew; Porunelloor A Mathew
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

9.  Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients.

Authors:  Zhuwei Xu; Tao Zhang; Ran Zhuang; Yun Zhang; Wei Jia; Chaojun Song; Kun Yang; Angang Yang; Boquan Jin
Journal:  BMC Immunol       Date:  2009-06-02       Impact factor: 3.615

10.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.

Authors:  Cameron S Brandt; Myriam Baratin; Eugene C Yi; Jacob Kennedy; Zeren Gao; Brian Fox; Betty Haldeman; Craig D Ostrander; Tomonori Kaifu; Christian Chabannon; Alessandro Moretta; Robert West; Wenfeng Xu; Eric Vivier; Steven D Levin
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.